• Explore /
  • Poster
  • / The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

Abstract Video & Slides Poster

Authors

null

Crescens Diane Tiu

The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Crescens Diane Tiu , Sarah Derby , Noor Md Haris , Liam Welsh , Anna Stansfeld , Thomas Hundsberger , Patrick Roth , Fatima König , Joel Robert Eisner , Malte Kleinschmidt , Stephanie Anderson , Felix Bachmann , Heidi A Lane , Marc Engelhardt , Thomas Kaindl , Karine Litherland , Alexandru C Stan , T.R. Jeffry Evans , Elizabeth Ruth Plummer , Juanita Suzanne Lopez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

02490800

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2068)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2068

Abstract #

TPS2068

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Juanita Suzanne Lopez

First Author: Magdalena Skowronska

First Author: Patrick Y. Wen

First Author: Alvaro Henrique Ingles Garces